Non-interventional, Post-marketing Study to Evaluate the Correlation Between Clinical and Biological Factors and IPI as Prognostic Factors in Patients With DLBCL in First Line Treatment With R-CHOP
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Lymphoma, B-Cell
Both
Lymphoma, B-Cell
Trial Information
Non-interventional, Post-marketing Study to Evaluate the Correlation Between Clinical and Biological Factors and IPI as Prognostic Factors in Patients With DLBCL in First Line Treatment With R-CHOP
Inclusion Criteria:
- Adult patients, >18 years of age
- Patients with diagnosed diffuse large B-cell lymphoma in first-line treatment with
R-CHOP
Exclusion Criteria:
- Prior chemotherapy treatment for diffuse large B-cell lymphoma
- Contra-indications or exclusion criteria according to the Summary of Product
Characteristics for MabThera/Rituxan
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Treatment patterns in clinical practice: Number of treatment cycles received
Outcome Time Frame:
approximately 3 years
Safety Issue:
No
Principal Investigator
Clinical Trials
Investigator Role:
Study Director
Investigator Affiliation:
Hoffmann-La Roche
Authority:
Romania: National Agency for Medicines and Medical Devices
Study ID:
ML28497
NCT ID:
NCT01724294
Start Date:
December 2012
Completion Date:
August 2015
Related Keywords:
- Lymphoma, B-Cell
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
Name | Location |
|---|
